| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BPIFB1 |
| Uniprot No | Q8TDL5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-484aa |
| 氨基酸序列 | MAGPWTFTLL CGLLAATLIQ ATLSPTAVLI LGPKVIKEKL TQELKDHNAT SILQQLPLLS AMREKPAGG IPVLGSLVNT VLKHIIWLKV ITANILQLQV KPSANDQELL VKIPLDMVAG FNTPLVKTI VEFHMTTEAQ ATIRMDTSAS GPTRLVLSDC ATSHGSLRIQ LLHKLSFLVN ALAKQVMNL LVPSLPNLVK NQLCPVIEAS FNGMYADLLQ LVKVPISLSI DRLEFDLLYP AIKGDTIQL YLGAKLLDSQ GKVTKWFNNS AASLTMPTLD NIPFSLIVSQ DVVKAAVAAV LSPEEFMVL LDSVLPESAH RLKSSIGLIN EKAADKLGST QIVKILTQDT PEFFIDQGHA KVAQLIVLE VFPSSEALRP LFTLGIEASS EAQFYTKGDQ LILNLNNISS DRIQLMNSGI GWFQPDVLK NIITEIIHSI LLPNQNGKLR SGVPVSLVKA LGFEAAESSL TKDALVLTPA SLWKPSSPV SQ |
| 预测分子量 | 52 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BPIFB1重组蛋白的3篇代表性文献摘要：
1. **《BPIFB1 promotes oral squamous cell carcinoma metastasis via activating NF-κB signaling》**
- **作者**: Zhang et al. (2020)
- **摘要**: 研究利用重组BPIFB1蛋白处理口腔癌细胞，发现其通过激活NF-κB通路增强细胞迁移和侵袭能力，提示BPIFB1在肿瘤转移中的促癌作用。
2. **《Expression and purification of recombinant BPIFB1 in a mammalian system for functional analysis》**
- **作者**: Lee et al. (2018)
- **摘要**: 报道了一种高效哺乳动物表达系统制备重组BPIFB1蛋白的方法，并通过质谱和ELISA验证其结构完整性，为后续功能研究提供基础。
3. **《Antimicrobial activity of BPIFB1 recombinant protein against Gram-negative bacteria》**
- **作者**: Chen et al. (2019)
- **摘要**: 实验显示重组BPIFB1蛋白对大肠杆菌等革兰氏阴性菌具有剂量依赖性抑菌作用，机制可能与破坏细菌膜结构相关。
4. **《BPIFB1 modulates airway inflammation through interaction with surfactant proteins》**
- **作者**: Wang et al. (2021)
- **摘要**: 研究发现重组BPIFB1蛋白通过与肺表面活性蛋白SP-A结合，调控巨噬细胞炎症因子释放，影响慢性阻塞性肺病进程。
注：以上为模拟文献案例，实际研究中建议通过PubMed或Web of Science查询最新论文。
BPIFB1 (BPI fold-containing family B member 1), also known as LPLUNC1 or C20orf185. is a member of the bactericidal/permeability-increasing protein (BPI) family. This protein family is characterized by conserved BPI structural domains that exhibit lipid-binding and antimicrobial properties. BPIFB1 is predominantly expressed in mucosal tissues, including the oral cavity, respiratory tract, and gastrointestinal system, suggesting a role in innate immunity and host defense against pathogens. Its gene is located on chromosome 20q11.21 and encodes a secreted protein containing two BPI-like domains, which may interact with bacterial lipopolysaccharides (LPS) to modulate inflammatory responses.
Recombinant BPIFB1 protein is engineered for experimental studies to elucidate its biological functions. Research indicates its involvement in multiple pathways: it may regulate cell proliferation, apoptosis, and inflammatory signaling, potentially through interactions with TLR4 or other immune receptors. Dysregulation of BPIFB1 has been linked to diseases such as chronic rhinosinusitis, inflammatory bowel disease (IBD), and cancers (e.g., lung, head/neck). In cancer contexts, BPIFB1 shows dual roles—acting as a tumor suppressor in some malignancies while promoting metastasis in others, possibly depending on tissue-specific microenvironments.
Recent studies highlight BPIFB1's therapeutic potential. Recombinant forms are used in vitro and in vivo to explore its antimicrobial, anti-inflammatory, or antitumor effects. Structural analyses via X-ray crystallography or NMR aim to map functional regions for drug design. Despite progress, its precise mechanisms remain incompletely understood, necessitating further research into its interactions with pathogens, immune cells, and epithelial barriers. Recombinant BPIFB1 serves as a critical tool for decoding its pathophysiological roles and developing targeted therapies.
×
